We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Illumina Inc (ILMN) is a leading diagnostics & research business with stocks listed in the US. It opened the day at US$461.54 after a previous close of US$459.25. During the day the price has varied from a low of USD457.78 to a high of USD465.59. The latest price was USD458.21 (25 minute delay). Illumina is listed on the NASDAQ. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| Open | US$461.54 |
|---|---|
| High | US$465.59 |
| Low | US$457.78 |
| Close | US$458.21 |
| Previous close | US$459.25 |
| Change | US$-1.04 |
| Change % | -0.2265% |
| Volume | 444,215 |
| 52-week range | US$288.01 - US$526 |
|---|---|
| 50-day moving average | US$442.8824 |
| 200-day moving average | US$439.359 |
| Target price | US$453.31 |
| PE ratio | 78.514 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$5.222 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $458.21
| 1 week (2021-10-08) | 11.76% |
|---|---|
| 1 month (2021-09-15) | 1.85% |
| 3 months (2021-07-15) | -0.93% |
| 6 months (2021-04-15) | 13.99% |
| 1 year (2020-10-15) | 41.52% |
|---|---|
| 2 years (2019-10-15) | 46.78% |
| 3 years (2018-10-15) | 46.20% |
| 5 years (2016-10-14) | 232.04% |
Valuing Illumina stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Illumina's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Illumina's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 79x. In other words, Illumina shares trade at around 79x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Illumina's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4485. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Illumina's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Illumina's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$843 million (£0.0 million).
The EBITDA is a measure of a Illumina's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$4 billion |
|---|---|
| Operating margin TTM | 16.36% |
| Gross profit TTM | US$2.2 billion |
| Return on assets TTM | 5.1% |
| Return on equity TTM | 15.79% |
| Profit margin | 19.39% |
| Book value | 35.238 |
| Market capitalisation | US$64.2 billion |
TTM: trailing 12 months
There are currently 2.4 million Illumina shares held short by investors – that's known as Illumina's "short interest". This figure is 10.6% up from 2.2 million last month.
There are a few different ways that this level of interest in shorting Illumina shares can be evaluated.
Illumina's "short interest ratio" (SIR) is the quantity of Illumina shares currently shorted divided by the average quantity of Illumina shares traded daily (recently around 825369.3877551). Illumina's SIR currently stands at 2.94. In other words for every 100,000 Illumina shares traded daily on the market, roughly 2940 shares are currently held short.
However Illumina's short interest can also be evaluated against the total number of Illumina shares, or, against the total number of tradable Illumina shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Illumina's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Illumina shares in existence, roughly 20 shares are currently held short) or 0.0166% of the tradable shares (for every 100,000 tradable Illumina shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Illumina.
Find out more about how you can short Illumina stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Illumina.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 9.18
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Illumina's overall score of 9.18 (as at 12/31/2018) is excellent – landing it in it in the 2nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Illumina is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.22/100
Illumina's environmental score of 2.22 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 2.6/100
Illumina's social score of 2.6 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.36/100
Illumina's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Illumina is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Illumina scored a 1 out of 5 for controversy – the highest score possible, reflecting that Illumina has managed to keep its nose clean.
Illumina Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 9.18 |
|---|---|
| Total ESG percentile | 2.42 |
| Environmental score | 2.22 |
| Environmental score percentile | 2 |
| Social score | 2.6 |
| Social score percentile | 2 |
| Governance score | 5.36 |
| Governance score percentile | 2 |
| Level of controversy | 1 |
We're not expecting Illumina to pay a dividend over the next 12 months.
Illumina's shares were split on a 2:1 basis on 22 September 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Illumina shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Illumina shares which in turn could have impacted Illumina's share price.
Over the last 12 months, Illumina's shares have ranged in value from as little as US$288.01 up to US$526. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Illumina's is 0.9529. This would suggest that Illumina's shares are less volatile than average (for this exchange).
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.
Shares in the trans-Tasman dairy company are down 55% over the last 12 months.
Shares in the Brisbane-based lender have risen nearly 60% in the last 12 months.
Everything we know about the Tissue Repair IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Illuvium (ILV) token as well as a list of exchanges you can trade it on.
Westpac shares are up 43% over the past 12 months.
Airports, travel agents and pubs are set to soar post lockdown, but should share investors look beyond immediate short-term wins?
Shares in the insurer are up just 10% in the last 12 months.
Everything we know about the Nimy Resources IPO, plus information on how to buy in.
The payment services company’s shares are up 16% in the last year.
Everything we know about the Parabellum Resources IPO, plus information on how to buy in.
